CA2436526A1 - Heterocyclic sulfonamide inhibitors of beta amyloid production - Google Patents
Heterocyclic sulfonamide inhibitors of beta amyloid production Download PDFInfo
- Publication number
- CA2436526A1 CA2436526A1 CA002436526A CA2436526A CA2436526A1 CA 2436526 A1 CA2436526 A1 CA 2436526A1 CA 002436526 A CA002436526 A CA 002436526A CA 2436526 A CA2436526 A CA 2436526A CA 2436526 A1 CA2436526 A1 CA 2436526A1
- Authority
- CA
- Canada
- Prior art keywords
- sulfonamide
- thiophene
- substituted
- chloro
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Abstract
Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z a re as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are described.
Claims (31)
1. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is selected from the group consisting of W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is selected from the group consisting of W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
2. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W is C, wherein W provides the point of attachment to the SO2 group;
X is S;
Y and Z are independently C or CR10;
R10 is selected from the group consisting of hydrogen and halogen;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W is C, wherein W provides the point of attachment to the SO2 group;
X is S;
Y and Z are independently C or CR10;
R10 is selected from the group consisting of hydrogen and halogen;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
3. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is halogen;
T is W is C, wherein W provides the point of attachment to the SO2 group;
X is S;
Y and Z are independently C or CR10;
R10 is selected from the group consisting of hydrogen and halogen;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is halogen;
T is W is C, wherein W provides the point of attachment to the SO2 group;
X is S;
Y and Z are independently C or CR10;
R10 is selected from the group consisting of hydrogen and halogen;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
4. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are hydrogen;
R3 is hydrogen;
R4 is a lower alkyl of S-stereochemistry;
R5 is hydrogen;
R6 is halogen;
T is X is S;
W, Y and Z are C, wherein W provides the point of attachment to the SO2 group.
wherein:
R1 and R2 are hydrogen;
R3 is hydrogen;
R4 is a lower alkyl of S-stereochemistry;
R5 is hydrogen;
R6 is halogen;
T is X is S;
W, Y and Z are C, wherein W provides the point of attachment to the SO2 group.
5. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are hydrogen;
R3 is hydrogen;
R4 is a lower alkyl of S-stereochemistry;
R5 is hydrogen;
R6 is hydrogen or halogen;
T is X is O;
W, Y and Z are C, wherein W provides the point of attachment to the SO2 group.
wherein:
R1 and R2 are hydrogen;
R3 is hydrogen;
R4 is a lower alkyl of S-stereochemistry;
R5 is hydrogen;
R6 is hydrogen or halogen;
T is X is O;
W, Y and Z are C, wherein W provides the point of attachment to the SO2 group.
6. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
7. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower allyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1,3)dioxane, where n is 2 to 5;
R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl(substituted)alkyl, alkylOH, substituted alkylOH, alkylOBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH)phenyl, CH(OH)substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted 2-indane, phenyl, substituted phenyl, alkylNHR7, and substituted alkylNHR7;
with the proviso that R3 and R4 are not both hydrogen;
R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8;
R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl;
or R3 and R4 may be joined to form a ring;
R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9;
Q is O, NH or S;
R9 is lower alkyl, substituted lower allyl, phenyl, or substituted phenyl;
R6 is selected from the group consisting of hydrogen, halogen and CF3;
T is W, Y and Z are independently selected from the group consisting of C, CR10 and N;
R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C;
X is selected from the group consisting of O, S, SO2, and NR11;
R11 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.
8. The compound according to any of claims 1, 2, or 5 to 7, wherein R6 is halogen.
9. The compound according to any of claims 1 to 8, wherein R6 is chlorine or bromine.
10. The compound according to any of claims 1 to 3, wherein T is C(OH)R1R2 and R1 and R2 are each hydrogen.
11. The compound according to any of claims 1 to 7, wherein W and Z are both C.
12. The compound according to any of claims 1 to 3, 6 or 7, wherein R4 is lower alkyl of S-stereochemistry.
13. The compound according to any of claims 1 to 3 or 5 to 7, wherein X
is S, W is C, Z is C, R6 is halogen, R4 is lower alkyl of S-stereochemistry, R3 is hydrogen, R5 is hydrogen, and R1 and R2 are each hydrogen.
is S, W is C, Z is C, R6 is halogen, R4 is lower alkyl of S-stereochemistry, R3 is hydrogen, R5 is hydrogen, and R1 and R2 are each hydrogen.
14. The compound according to any of claims 1 to 3, 6, or 7, wherein R3CR4 is cyclohexyl.
15. The compound according to any of claims 1 to 3, 6, or 7, wherein R3CR4 is piperidine or N-substituted piperidine.
16. The compound according to any of claims 1 to 3, 6, or 7, wherein X is S, and W, Y and Z are independently C or CR10.
17. The compound according to claim 1, wherein the compound is selected from the group consisting of:
3-bromo-5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
4-bromo-5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
2,5-dichloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-3-sulfonamide;
4,5-dichloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
4,5-dibromo-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-cyclohexyl-2-hydroxyethyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-cyclohexyl-2-hydroxyethyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide 1,1-dioxide;
5-chloro-N-[1-(hydroxymethyl)-2,3-dimethylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[2-ethyl-1-(hydroxymethyl)hexyl]thiophene-2-sulfonamide;
5-chloro-N-[2-hydroxy-1-(2,4,6-trimethylcyclohex-3-en-1-yl)ethyl]thiophene2-sulfonamide;
5-chloro-N-(1-cyclohex-3-en-1-yl-2-hydroxyethyl)thiophene-2-sulfonamide;
5-chloro-N-(1-cyclopentyl-2-hydroxyethyl)thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-(hydroxymethyl)-1,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-1,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2,4-dimethylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-methyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-4-methyl-2-propylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-propyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-phenylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-2-propyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)heptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-isobutylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)heptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-pentyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-phenylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
S-chloro-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-phenylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
S-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-isopropyloctyl]thiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)butyl]-5-chlorothiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)-4-methylpentyl]-5-chlorothiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2,4-dimethylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-methyloctyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-4-methyl-2-propylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)heptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-isobutylheptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)heptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-pentyloctyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-phenylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-pyridin-3-ylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-isopropyl-4-methylpeniyl]thiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)butyl]-5-bromothiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)butyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-(ethylamino)-2-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)butyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)heptyl]-2-thiophenesulfonamide;
N-[(1S)-2-(benzylamino)-1-(hydroxymethyl)propyl]-5-chloro-2-thiophenesulfonamide;
N-[(1S)-2-(benzylamino)-1-(hydroxymethyl)butyl]-5-chloro-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-(cyclopentylamino)-1-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-N-(2-phenoxyethyl)thiophene-2-sulfonamide;
5-chloro-N-(3-chlorobenzyl)-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-(2-hydroxy-1,1-dimethylethyl)thiophene-2-sulfonamide;
N-[1,1-bis(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)cyclopentyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]thiophene-2-sulfonamide;
N-[(S)-1-benzyl-2-hydroxyethyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)-2,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
N-[R-2-(benzylthio)-1-(hydroxymethyl)ethyl]-5-chlorothiophene-2-sulfonamide;
N-[(R,S)-2-(benzyloxy)-1-(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-bromo-N-(2-hydroxy-1,1-dimethylethyl)thiophene-2-sulfonamide;
N-[1,1-bis(hydroxymethyl)propyl]-5-bromothiophene-2-sulfonamide 5-bromo-N-[1-(hydroxymethyl)cyclopentyl]thiophene-2-sulfonamide 5-bromo-N-[(S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-3-(methylthio)propyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-2,2-dimethylpropyl]thiophene-2-sulfonamide;
N-[R-2-(benzylthio)-1-(hydroxymethyl)ethyl]-5-bromothiophene-2-sulfonamide;
5-bromo-N-(R-2-hydroxy-1-{[(3-methylbenzyl)thio]methyl}ethyl)thiophene-2-sulfonamide;
N-{(S)-1-[4-(benzyloxy)benzyl]-2-hydroxyethyl}-5-bromothiophene-2-sulfonamide;
5-bromo-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-formyl-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-(1-hydroxyethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[cyclopentyl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]octyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]heptyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hexyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3,3-dimethyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(4-fluorophenyl)(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(4-chlorophenyl)(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[hydroxy(4-methoxyphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-4-(1,3-dioxan-2-yl)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[4-(methylthio)phenyl]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[[4-(dimethylamino)phenyl](hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[cyclopentyl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]octyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]heptyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hexyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[hydroxy(2-methylphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-3,3-dimethyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[hydroxy(4-methoxyphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-4-(1,3-dioxan-2-yl)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-3-ynyl}thiophene-2-sulfonamide;
N-((S,S)-1-{hydroxy[4-(methylthio)phenyl]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
N-{(S,S)-1-[[4-(dimethylamino)phenyl](hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(S)-cyclohex-2-en-1-yl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S,E)-2-hydroxy-1-[(S)-1-methylpropyl]hex-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R,E)-2-hydroxy-1-[(S)-1-methylpropyl]hex-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R,E)-2-hydroxy-1-[(S)-1-methylpropyl]hept-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-1-[(S)-1-methylpropyl]-5-phenylpent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-(1-hydroxy-1-methylethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]-2-pentylheptyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[hydroxy(diphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-allyl-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-{(S)-2-ethyl-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[bis(4-chlorophenyl)(hydroxy)methyl]-2-methylbutyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-2-isopropenyl-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[bis(4-methoxyphenyl)]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-3-methyl-2-[(E)-1-methylprop-1-enyl]-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
N-{(S)-2-but-3-enyl-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[di(1-naphthyl)]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-ethyl-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-hydroxy-2-isopropenyl-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,E)-2-hydroxy-3-methyl-2-[(E)-1-methylprop-1-enyl]-1- [(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-but-3-enyl-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[2-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2,3-dihydro-H-inden-1-yl]thiophene-2-sulfonamide;
5-chloro-N-[2-(hydroxymethyl)-2,3-dihydro-H-inden-2-yl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)cyclohexyl]thiophene-2-sulfonamide;
5-bromo-N-[2-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]thiophene-2-sulfonamide;
5-bromo-N-[2-(hydroxymethyl)-2,3-dihydro-H-inden-2-yl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(S)-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[R-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-1-[(S)-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-1-[R-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
S-chloro-N-[(S,S)-2-methyl-1-(2,2,2-trifluoro-1-hydroxyethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(1-hydroxybut-3-enyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[ 1-( 1-hydroxy-3-methylbut-3-enyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-methoxycyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-propoxycyclohexyl)ethyl]thiophene-2-sulfonamide;
N-{(S)-1-[4-(allyloxy)cyclohexyl]-2-hydroxyethyl}-5-chlorothiophene-2-sulfonamide;
N-{(S)-1-[4-(benzyloxy)cyclohexyl]-2-hydroxyethyl}-5-chlorothiophene-2-sulfonamide;
N-[1-acetyl-4-(hydroxymethyl)piperidin-4-yl]-5-chlorothiophene-2-sulfonamide;
N-[(1S)-2-butyl-1-(hydroxymethyl)hexyl]-5-chloro-2-thiophenesulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-5-iodo-2-thiophenesulfonamide;
5-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-2-thiophenesulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-benzylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-ethylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-npropylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-allylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(3-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-morpholinocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(4-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(2-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(carboethoxymethyl)aminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-Chloro-N-[(S)-2-hydroxy-1-(4-hydroxycyclohexyl)ethyl]thiophene-2-sulfonamide 5-chloro-N-[(S)-2-ethyl-1-formylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-ethyl-1-(1-hydroxyethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-ethyl-1-(1-hydroxy-1-methylethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-(2-hydroxy-1-tetrahydro-H-thiopyran-4-ylethyl)thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-piperidin-4-ylethyl]thiophene-2-sulfonamide;
N-[(S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
N-[(S)-2-ethyl-1-(hydroxymethyl)butyl]-5-fluorothiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(2,3-dihydro-H-inden-2-yl)-2-hydroxyethyl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(Z-(hydroxyimino)methyl]-2-methylbutyl}thiophene-2-sulfonamide; and 5-chloro-N-{(S,S)-1-[(E)-(hydroxyimino)methyl]-2-methylbutyl}thiophene-2-sulfonamide.
3-bromo-5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
4-bromo-5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
2,5-dichloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-3-sulfonamide;
4,5-dichloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
4,5-dibromo-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-cyclohexyl-2-hydroxyethyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-cyclohexyl-2-hydroxyethyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide 1,1-dioxide;
5-chloro-N-[1-(hydroxymethyl)-2,3-dimethylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[2-ethyl-1-(hydroxymethyl)hexyl]thiophene-2-sulfonamide;
5-chloro-N-[2-hydroxy-1-(2,4,6-trimethylcyclohex-3-en-1-yl)ethyl]thiophene2-sulfonamide;
5-chloro-N-(1-cyclohex-3-en-1-yl-2-hydroxyethyl)thiophene-2-sulfonamide;
5-chloro-N-(1-cyclopentyl-2-hydroxyethyl)thiophene-2-sulfonamide;
5-bromo-N-[(1S)-1-(hydroxymethyl)-1,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-1,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2,4-dimethylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-methyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-4-methyl-2-propylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-propyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-phenylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-2-propyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)heptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-isobutylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)heptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-pentyloctyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-1-(hydroxymethyl)-2-phenylheptyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
S-chloro-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-phenylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
S-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-isopropyloctyl]thiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)butyl]-5-chlorothiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)-4-methylpentyl]-5-chlorothiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2,4-dimethylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-methyloctyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-4-methyl-2-propylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)heptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-isobutylheptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-(4-methoxyphenyl)heptyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-1-(hydroxymethyl)-2-pentyloctyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylpropyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-phenylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-phenylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-4-methyl-2-pyridin-3-ylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)-4-methylpentyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-(2-furyl)-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-1-(hydroxymethyl)-2-isopropyl-4-methylpeniyl]thiophene-2-sulfonamide;
N-[(1S,2S)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)butyl]-5-bromothiophene-2-sulfonamide;
5-chloro-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2R)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-bromo-N-[(1S,2S)-2-ethyl-1-(hydroxymethyl)octyl]thiophene-2-sulfonamide;
5-chloro-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)butyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-(ethylamino)-2-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)butyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-[(2-hydroxyethyl)amino]-1-(hydroxymethyl)heptyl]-2-thiophenesulfonamide;
N-[(1S)-2-(benzylamino)-1-(hydroxymethyl)propyl]-5-chloro-2-thiophenesulfonamide;
N-[(1S)-2-(benzylamino)-1-(hydroxymethyl)butyl]-5-chloro-2-thiophenesulfonamide;
5-chloro-N-[(1S)-2-(cyclopentylamino)-1-(hydroxymethyl)propyl]-2-thiophenesulfonamide;
5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-N-(2-phenoxyethyl)thiophene-2-sulfonamide;
5-chloro-N-(3-chlorobenzyl)-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-chloro-N-(2-hydroxy-1,1-dimethylethyl)thiophene-2-sulfonamide;
N-[1,1-bis(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)cyclopentyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]thiophene-2-sulfonamide;
N-[(S)-1-benzyl-2-hydroxyethyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)-2,2-dimethylpropyl]thiophene-2-sulfonamide;
5-chloro-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
N-[R-2-(benzylthio)-1-(hydroxymethyl)ethyl]-5-chlorothiophene-2-sulfonamide;
N-[(R,S)-2-(benzyloxy)-1-(hydroxymethyl)propyl]-5-chlorothiophene-2-sulfonamide;
5-chloro-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-3-methylbutyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)pentyl]thiophene-2-sulfonamide;
5-bromo-N-(2-hydroxy-1,1-dimethylethyl)thiophene-2-sulfonamide;
N-[1,1-bis(hydroxymethyl)propyl]-5-bromothiophene-2-sulfonamide 5-bromo-N-[1-(hydroxymethyl)cyclopentyl]thiophene-2-sulfonamide 5-bromo-N-[(S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-3-(methylthio)propyl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
5-bromo-N-[(S)-1-(hydroxymethyl)-2,2-dimethylpropyl]thiophene-2-sulfonamide;
N-[R-2-(benzylthio)-1-(hydroxymethyl)ethyl]-5-bromothiophene-2-sulfonamide;
5-bromo-N-(R-2-hydroxy-1-{[(3-methylbenzyl)thio]methyl}ethyl)thiophene-2-sulfonamide;
N-{(S)-1-[4-(benzyloxy)benzyl]-2-hydroxyethyl}-5-bromothiophene-2-sulfonamide;
5-bromo-N-[(R,R)-2-hydroxy-1-(hydroxymethyl)propyl]thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-formyl-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-(1-hydroxyethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[cyclopentyl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]octyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]heptyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hexyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3,3-dimethyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(4-fluorophenyl)(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(4-chlorophenyl)(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[hydroxy(4-methoxyphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-3-methyl-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-4-(1,3-dioxan-2-yl)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[4-(methylthio)phenyl]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[[4-(dimethylamino)phenyl](hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[cyclopentyl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]octyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]heptyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hexyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[hydroxy(2-methylphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-3,3-dimethyl-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[hydroxy(4-methoxyphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-4-(1,3-dioxan-2-yl)-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-3-ynyl}thiophene-2-sulfonamide;
N-((S,S)-1-{hydroxy[4-(methylthio)phenyl]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
N-{(S,S)-1-[[4-(dimethylamino)phenyl](hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(S)-cyclohex-2-en-1-yl(hydroxy)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S,E)-2-hydroxy-1-[(S)-1-methylpropyl]hex-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R,E)-2-hydroxy-1-[(S)-1-methylpropyl]hex-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R,E)-2-hydroxy-1-[(S)-1-methylpropyl]hept-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-4-methyl-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-1-[(S)-1-methylpropyl]-5-phenylpent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-[(S,S)-1-(1-hydroxy-1-methylethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-1-[(S)-1-methylpropyl]-2-pentylheptyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[hydroxy(diphenyl)methyl]-2-methylbutyl}thiophene-2-sulfonamide;
N-{(S)-2-allyl-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-{(S)-2-ethyl-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
N-{(S,S)-1-[bis(4-chlorophenyl)(hydroxy)methyl]-2-methylbutyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-{(S)-2-hydroxy-2-isopropenyl-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[bis(4-methoxyphenyl)]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-chloro-N-{(S,E)-2-hydroxy-3-methyl-2-[(E)-1-methylprop-1-enyl]-1-[(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
N-{(S)-2-but-3-enyl-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}-5-chlorothiophene-2-sulfonamide;
5-chloro-N-((S,S)-1-{hydroxy[di(1-naphthyl)]methyl}-2-methylbutyl)thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-ethyl-2-hydroxy-1-[(S)-1-methylpropyl]butyl}thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-hydroxy-2-isopropenyl-3-methyl-1-[(S)-1-methylpropyl]but-3-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,E)-2-hydroxy-3-methyl-2-[(E)-1-methylprop-1-enyl]-1- [(S)-1-methylpropyl]pent-3-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S)-2-but-3-enyl-2-hydroxy-1-[(S)-1-methylpropyl]hex-5-enyl}thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[2-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]thiophene-2-sulfonamide;
5-chloro-N-[1-(hydroxymethyl)-2,3-dihydro-H-inden-1-yl]thiophene-2-sulfonamide;
5-chloro-N-[2-(hydroxymethyl)-2,3-dihydro-H-inden-2-yl]thiophene-2-sulfonamide;
5-bromo-N-[1-(hydroxymethyl)cyclohexyl]thiophene-2-sulfonamide;
5-bromo-N-[2-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]thiophene-2-sulfonamide;
5-bromo-N-[2-(hydroxymethyl)-2,3-dihydro-H-inden-2-yl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(S)-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[R-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-chloro-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-1-[(S)-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-1-[R-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pentyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,S)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
5-bromo-N-{(S,R)-2-hydroxy-1-[(S)-1-methylpropyl]pent-4-enyl}thiophene-2-sulfonamide;
S-chloro-N-[(S,S)-2-methyl-1-(2,2,2-trifluoro-1-hydroxyethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[1-(1-hydroxybut-3-enyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[ 1-( 1-hydroxy-3-methylbut-3-enyl)cyclohexyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-methoxycyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-propoxycyclohexyl)ethyl]thiophene-2-sulfonamide;
N-{(S)-1-[4-(allyloxy)cyclohexyl]-2-hydroxyethyl}-5-chlorothiophene-2-sulfonamide;
N-{(S)-1-[4-(benzyloxy)cyclohexyl]-2-hydroxyethyl}-5-chlorothiophene-2-sulfonamide;
N-[1-acetyl-4-(hydroxymethyl)piperidin-4-yl]-5-chlorothiophene-2-sulfonamide;
N-[(1S)-2-butyl-1-(hydroxymethyl)hexyl]-5-chloro-2-thiophenesulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-5-iodo-2-thiophenesulfonamide;
5-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-2-thiophenesulfonamide;
N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-benzylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-ethylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-npropylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-allylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(3-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-morpholinocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(4-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(2-pyridyl)methylaminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-(4-(carboethoxymethyl)aminocyclohexyl)ethyl]thiophene-2-sulfonamide;
5-Chloro-N-[(S)-2-hydroxy-1-(4-hydroxycyclohexyl)ethyl]thiophene-2-sulfonamide 5-chloro-N-[(S)-2-ethyl-1-formylbutyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-ethyl-1-(1-hydroxyethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-ethyl-1-(1-hydroxy-1-methylethyl)butyl]thiophene-2-sulfonamide;
5-chloro-N-(2-hydroxy-1-tetrahydro-H-thiopyran-4-ylethyl)thiophene-2-sulfonamide;
5-chloro-N-[(S)-2-hydroxy-1-piperidin-4-ylethyl]thiophene-2-sulfonamide;
N-[(S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;
N-[(S)-2-ethyl-1-(hydroxymethyl)butyl]-5-fluorothiophene-2-sulfonamide;
5-chloro-N-[(S)-1-(2,3-dihydro-H-inden-2-yl)-2-hydroxyethyl]thiophene-2-sulfonamide;
5-chloro-N-{(S,S)-1-[(Z-(hydroxyimino)methyl]-2-methylbutyl}thiophene-2-sulfonamide; and 5-chloro-N-{(S,S)-1-[(E)-(hydroxyimino)methyl]-2-methylbutyl}thiophene-2-sulfonamide.
18. The compound according to claim 1, wherein the compound is 5-chloro-N-[(1S)-2-ethyl-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide.
19. The compound according to claim 1 or 5, wherein X is O, and W, Y
and Z are independently selected from C and CR10.
and Z are independently selected from C and CR10.
20. The compound according to claim 19, wherein R6 is halogen, R4 is lower alkyl of S-stereochemistry, R3 is hydrogen, R5 is hydrogen, and R1 and R2 are each hydrogen.
21. The compound according to claim 1, wherein the compound is selected from the group consisting of N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-2-furansulfonamide and 5-chloro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]-2-furansulfonamide.
22. The compound according to claim 1, wherein the compound is 4-[1-(5-chloro-thiophene-2-sulfonylamino)-2-hydroxy-ethyl]-piperidine-1-carboxylic acid tert-butyl ester.
23. The compound according to any of claims 1 to 22, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts of acetic acid, lactic acid, citric acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malonic acid, mandelic acid, malic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, toluenesulfonic acid, salts of bases, and mixtures thereof.
24. A pharmaceutical composition comprising a compound according to any of claims 1 to 23 and a physiologically compatible carrier.
25. A method of inhibiting beta amyloid production in a subject, said method comprising the step of delivering a compound according to any of claims to 23.
26. The method according to claim 25, wherein said compound is delivered orally or by injection.
27. A method of treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, and Down's syndrome, in a subject, said method comprising the step of administering a compound according to any of claims 1 to 23 to said subject in an amount sufficient to alleviate the symptoms or progress of said disease.
28. Use of the compound according to any of claims 1 to 23, or said acceptable salt thereof, in preparing a medicament.
29. Use of the compound according to any of claims 1 to 23, or said acceptable salt, in preparing a medicament useful for administration to a mammalian subject for inhibiting beta amyloid production.
30. The use according to claim 29, wherein said compound is administered orally or by injection.
31. Use of the compound according to any of claims 1 to 23, or said acceptable salt, in preparing a medicament useful for administration to a mammalian subject for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, and Down's syndrome, wherein said compound is administered in an amount sufficient to alleviate the symptoms or progress of said disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25510500P | 2000-12-13 | 2000-12-13 | |
US60/255,105 | 2000-12-13 | ||
PCT/US2001/048375 WO2002057252A2 (en) | 2000-12-13 | 2001-12-11 | Heterocyclic sulfonamide inhibitors of beta amyloid production |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2436526A1 true CA2436526A1 (en) | 2002-07-25 |
CA2436526C CA2436526C (en) | 2010-10-19 |
Family
ID=22966854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2436526A Expired - Fee Related CA2436526C (en) | 2000-12-13 | 2001-12-11 | Heterocyclic sulfonamide inhibitors of beta amyloid production |
Country Status (28)
Country | Link |
---|---|
US (5) | US6610734B2 (en) |
EP (1) | EP1341779B1 (en) |
JP (2) | JP2004517892A (en) |
KR (1) | KR100869061B1 (en) |
CN (2) | CN1263750C (en) |
AR (1) | AR035516A1 (en) |
AT (1) | ATE330950T1 (en) |
AU (1) | AU2002245123B2 (en) |
BR (1) | BR0116063A (en) |
CA (1) | CA2436526C (en) |
CY (1) | CY1105441T1 (en) |
DE (1) | DE60121032T2 (en) |
DK (1) | DK1341779T3 (en) |
EA (1) | EA009035B1 (en) |
ES (1) | ES2267853T3 (en) |
HK (1) | HK1059619A1 (en) |
HU (1) | HUP0303857A3 (en) |
IL (3) | IL156268A0 (en) |
MX (1) | MXPA03005255A (en) |
NO (1) | NO328885B1 (en) |
NZ (2) | NZ526213A (en) |
PL (1) | PL365950A1 (en) |
PT (1) | PT1341779E (en) |
SG (1) | SG128491A1 (en) |
SI (1) | SI1341779T1 (en) |
TW (1) | TWI235155B (en) |
WO (1) | WO2002057252A2 (en) |
ZA (1) | ZA200304135B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528076A (en) * | 2000-03-20 | 2003-09-24 | メルク シャープ エンド ドーム リミテッド | Sulfonamide-substituted bridged bicycloalkyl derivatives |
NZ526213A (en) * | 2000-12-13 | 2005-05-27 | Wyeth Corp | Heterocyclic sulfonamide inhibitors of beta amyloid production |
US6657070B2 (en) | 2000-12-13 | 2003-12-02 | Wyeth | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
BR0214863A (en) * | 2001-12-11 | 2004-12-14 | Wyeth Corp | Process for the synthesis of chirally pure beta-amino alcohols |
RU2321394C2 (en) * | 2002-06-11 | 2008-04-10 | Уайт | Substituted phenylsulfonamide inhibitors of beta-amyloid secretion |
DE60329316D1 (en) * | 2002-11-12 | 2009-10-29 | Merck & Co Inc | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER |
WO2004092155A1 (en) * | 2003-03-31 | 2004-10-28 | Wyeth | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
KR20060066057A (en) * | 2003-06-30 | 2006-06-15 | 다이이찌 세이야꾸 가부시기가이샤 | Heterocyclic methyl sulfone derivative |
CA2552558A1 (en) * | 2004-01-16 | 2005-08-11 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
WO2006078753A1 (en) | 2005-01-18 | 2006-07-27 | Elan Pharmaceuticals, Inc. | N-substituted heterocyclic sulfonamides |
CN101142194B (en) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
GB0602951D0 (en) * | 2006-02-14 | 2006-03-29 | Novartis Ag | Organic Compounds |
CN101384579A (en) * | 2006-02-17 | 2009-03-11 | 惠氏公司 | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
RU2008129797A (en) * | 2006-02-17 | 2010-03-27 | Вайет (Us) | METHODS FOR PRODUCING SULFONAMIDE-SUBSTITUTED ALCOHOLS AND THEIR INTERMEDIATE COMPOUNDS |
CA2649396A1 (en) * | 2006-04-21 | 2007-11-08 | Wyeth | Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof |
US7550629B2 (en) * | 2006-04-21 | 2009-06-23 | Wyeth | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors |
US7476762B2 (en) * | 2006-04-21 | 2009-01-13 | Wyeth | Methods for preparing sulfonamide compounds |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
WO2008059238A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
WO2008064320A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
CL2008000119A1 (en) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
AR067534A1 (en) * | 2007-07-16 | 2009-10-14 | Wyeth Corp | PROCESS FOR THE PREPARATION OF TRIFLUOROALQUIL - PHENYL SULFONAMIDS AND HETEROCICLIC SULFONAMIDS |
CL2008002059A1 (en) * | 2007-07-16 | 2008-11-14 | Wyeth Corp | Method of preparation of heterocyclic sulfonamides; intermediate compounds used in the described method; and the methods of preparing said intermediaries. |
EP2193117A1 (en) * | 2007-07-16 | 2010-06-09 | Wyeth a Corporation of the State of Delaware | Inhibitors of beta amyloid production |
WO2009082437A2 (en) | 2007-12-21 | 2009-07-02 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (sarms) and uses thereof |
AR070120A1 (en) * | 2008-01-11 | 2010-03-17 | Wyeth Corp | DERIVATIVES OF ARIL SULFONAMIDE CONTAINING O-SULFATE AND O-PHOSPHATE, USEFUL AS BETA-AMYLOID INHIBITORS, PREPARATION PROCESS OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
EP3586839A1 (en) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
JP2013514287A (en) | 2009-12-17 | 2013-04-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inhibitors of sphingosine kinase |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
CN105142627B (en) | 2013-01-18 | 2019-06-21 | 卡尔迪奥克斯尔制药公司 | Medical composition comprising nitroxyl donors |
CN104370769B (en) * | 2013-08-14 | 2017-05-31 | 重庆博腾制药科技股份有限公司 | A kind of method for preparing hydroxyadamantane glycine derivative |
WO2015108988A2 (en) | 2014-01-17 | 2015-07-23 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
US11046668B2 (en) | 2016-03-11 | 2021-06-29 | Ohio State Innovation Foundation | Small molecule antimicrobials |
DE202022106287U1 (en) | 2022-11-09 | 2022-11-21 | Ahmad Salawi | A method for the synthesis and biological evaluation of new sulfonamide analogues |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US656536A (en) * | 1899-12-28 | 1900-08-21 | David Fitzgibbons | Boiler. |
US3376523A (en) * | 1966-12-27 | 1968-04-02 | Univ California | Transient-suppressing magnetic transmission line |
US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
KR920019763A (en) | 1991-04-26 | 1992-11-19 | 모리다 가즈라 | Azole compounds, preparation methods and uses thereof |
GB9110722D0 (en) | 1991-05-17 | 1991-07-10 | Fujisawa Pharmaceutical Co | Amine derivatives |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
JP3599287B2 (en) * | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | Sulfonamide derivative |
US6342610B2 (en) * | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
NZ264143A (en) | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
US5519040A (en) | 1994-04-29 | 1996-05-21 | Allergan | Substituted thiazole sulfonamides as antiglaucoma agents |
US5561146A (en) * | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
JPH09136878A (en) * | 1995-09-12 | 1997-05-27 | Ono Pharmaceut Co Ltd | Tetrazole derivative |
EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
CA2238175A1 (en) * | 1995-11-28 | 1997-06-19 | Cephalon, Inc. | D-amino acid derived inhibitors of cysteine and serine proteases |
WO1997024340A1 (en) | 1995-12-27 | 1997-07-10 | Takeda Chemical Industries, Ltd. | Oxazole derivatives, their production and use |
JPH09235276A (en) * | 1995-12-27 | 1997-09-09 | Takeda Chem Ind Ltd | Oxazole derivative, production of the same and use of the same |
US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
JP2000515153A (en) | 1996-07-22 | 2000-11-14 | モンサント カンパニー | Thiolsulfonamide metalloprotease inhibitor |
US5703129A (en) | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
JP2001502330A (en) * | 1996-10-11 | 2001-02-20 | ワーナー―ランバート・コンパニー | Sulfonamide-substituted aspartate interleukin-1β converting enzyme inhibitor |
US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
HUP0001383A3 (en) | 1996-11-22 | 2001-11-28 | Lilly Co Eli | N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use |
DE19650196A1 (en) * | 1996-12-04 | 1998-06-10 | Bayer Ag | Thienylsulfonylamino (thio) carbonyl compounds |
GB9725138D0 (en) * | 1997-11-27 | 1998-01-28 | Pharmacia & Upjohn Spa | Thiophenesulfonamide compounds |
JPH11343279A (en) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | Sulfonamide derivative and tnf-alfa production inhibitor containing the same |
US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
EA200001247A1 (en) * | 1998-06-03 | 2001-08-27 | Джи Пи Ай Нил Холдингс, Инк. | N-BONDED SULPHONAMIDES OF N-HETEROCYCLIC CARBONIC ACIDS OR ISATERES OF CARBONIC ACIDS |
US7410995B1 (en) | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
AU773273B2 (en) | 1999-02-26 | 2004-05-20 | Bristol-Myers Squibb Company | Novel sulfonamide compounds and uses thereof |
CN1347411A (en) | 1999-04-19 | 2002-05-01 | 盐野义制药株式会社 | Sulfonamide derivs. having oxadiazole rings |
EP1088815A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
EP1222176A1 (en) * | 1999-10-08 | 2002-07-17 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
US6657070B2 (en) * | 2000-12-13 | 2003-12-02 | Wyeth | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
NZ526213A (en) * | 2000-12-13 | 2005-05-27 | Wyeth Corp | Heterocyclic sulfonamide inhibitors of beta amyloid production |
JP4615861B2 (en) | 2001-12-11 | 2011-01-19 | ワイス・エルエルシー | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
BR0214863A (en) | 2001-12-11 | 2004-12-14 | Wyeth Corp | Process for the synthesis of chirally pure beta-amino alcohols |
RU2321394C2 (en) * | 2002-06-11 | 2008-04-10 | Уайт | Substituted phenylsulfonamide inhibitors of beta-amyloid secretion |
WO2004092155A1 (en) | 2003-03-31 | 2004-10-28 | Wyeth | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
-
2001
- 2001-12-11 NZ NZ526213A patent/NZ526213A/en unknown
- 2001-12-11 CA CA2436526A patent/CA2436526C/en not_active Expired - Fee Related
- 2001-12-11 AT AT01993277T patent/ATE330950T1/en active
- 2001-12-11 KR KR1020037007928A patent/KR100869061B1/en not_active IP Right Cessation
- 2001-12-11 WO PCT/US2001/048375 patent/WO2002057252A2/en active Application Filing
- 2001-12-11 NZ NZ538100A patent/NZ538100A/en unknown
- 2001-12-11 CN CNB018205186A patent/CN1263750C/en not_active Expired - Fee Related
- 2001-12-11 IL IL15626801A patent/IL156268A0/en active IP Right Review Request
- 2001-12-11 DE DE60121032T patent/DE60121032T2/en not_active Expired - Lifetime
- 2001-12-11 AU AU2002245123A patent/AU2002245123B2/en not_active Ceased
- 2001-12-11 PL PL01365950A patent/PL365950A1/en not_active IP Right Cessation
- 2001-12-11 EP EP01993277A patent/EP1341779B1/en not_active Expired - Lifetime
- 2001-12-11 JP JP2002557933A patent/JP2004517892A/en not_active Withdrawn
- 2001-12-11 SG SG200503628A patent/SG128491A1/en unknown
- 2001-12-11 EA EA200300674A patent/EA009035B1/en not_active IP Right Cessation
- 2001-12-11 ES ES01993277T patent/ES2267853T3/en not_active Expired - Lifetime
- 2001-12-11 CN CNA2005100035919A patent/CN1800176A/en active Pending
- 2001-12-11 US US10/014,304 patent/US6610734B2/en not_active Expired - Fee Related
- 2001-12-11 PT PT01993277T patent/PT1341779E/en unknown
- 2001-12-11 BR BR0116063-0A patent/BR0116063A/en not_active Application Discontinuation
- 2001-12-11 MX MXPA03005255A patent/MXPA03005255A/en active IP Right Grant
- 2001-12-11 DK DK01993277T patent/DK1341779T3/en active
- 2001-12-11 HU HU0303857A patent/HUP0303857A3/en unknown
- 2001-12-11 SI SI200130604T patent/SI1341779T1/en unknown
- 2001-12-12 AR ARP010105782A patent/AR035516A1/en not_active Application Discontinuation
- 2001-12-12 TW TW090130721A patent/TWI235155B/en active
-
2003
- 2003-05-28 ZA ZA200304135A patent/ZA200304135B/en unknown
- 2003-06-02 IL IL156268A patent/IL156268A/en not_active IP Right Cessation
- 2003-06-05 US US10/455,674 patent/US6878742B2/en not_active Expired - Fee Related
- 2003-06-11 NO NO20032645A patent/NO328885B1/en not_active IP Right Cessation
-
2004
- 2004-03-02 HK HK04101538A patent/HK1059619A1/en not_active IP Right Cessation
-
2005
- 2005-03-16 US US11/081,784 patent/US7691884B2/en not_active Expired - Fee Related
-
2006
- 2006-09-14 CY CY20061101305T patent/CY1105441T1/en unknown
-
2008
- 2008-01-17 IL IL188853A patent/IL188853A0/en unknown
-
2009
- 2009-10-09 US US12/576,513 patent/US7842718B2/en not_active Expired - Fee Related
-
2010
- 2010-06-24 JP JP2010144307A patent/JP2010265280A/en not_active Withdrawn
- 2010-10-19 US US12/907,123 patent/US20110034513A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2436526A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
ES2217191T3 (en) | ASSOCIATION OF AN ANTAGONIST OF THE CB1 RECEIVER AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY. | |
US20070093492A1 (en) | Pyrrolidine derivatives | |
KR100802332B1 (en) | Novel 3-substituted urea derivatives and medicinal use thereof | |
RU2005137403A (en) | NEW SUBSTITUTED 3-Sulfur Indoles | |
JP2008542365A5 (en) | ||
JPH05246968A (en) | Ketone derivative | |
US20080058381A1 (en) | Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | |
JP2006501295A5 (en) | ||
RU2005111589A (en) | 1-pyridine-4-urea derivatives | |
RU2006134004A (en) | Heteroarylamino-pyrazole derivatives useful for the treatment of diabetes | |
CA2457037A1 (en) | Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments | |
JP2004508304A5 (en) | ||
RU2007101685A (en) | MODULATORS OF NICOTINE ACETYLCHOLINE ALPHA 7 RECEPTORS AND THEIR THERAPEUTIC APPLICATIONS | |
RU2009118254A (en) | PHENYLACETAMIDES AS PROTEINKINASE INHIBITORS | |
RU2007128085A (en) | QUALITY AMMONIUM SALTS AS AN M3 ANTAGONISTS | |
JP2006525299A (en) | Azetidine carboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders | |
RU2006128445A (en) | ACETYLINE PIPERAZINE COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | |
BRPI0213393B1 (en) | alkyl ether derivatives, or salts thereof, process for producing an alkyl ether derivative, alkyl amide derivative, or salts thereof, and a pharmaceutical composition | |
JP2007528884A5 (en) | ||
RU2004135567A (en) | MAJOR NEPEPTIDE BRADIKININ ANTAGONISTS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
TW201712004A (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
JP2009504762A5 (en) | ||
JP2006513222A5 (en) | ||
JPH02500029A (en) | Aryl-N-aminoalkyl-4-(sulfonamido)benzamide, antiarrhythmic agent and composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20121211 |